Resources
Blog: Read the latest post
The Science of Drug Development: Lessons from a Pioneer in Pharmaceutical Decision-Making
May 5, 2025
Jay Andersen, a pioneer in pharmaceutical decision-making, shared some lessons learned from developing portfolio management and probability assessment approaches.
Upcoming Webinar
Join us on May 28 for a webinar with Yael Weiss, CEO of Mahzi Therapeutics, and Alok Tayi, PhD, Founder and CEO of Vibe Bio, to explore:
- Best practices of BD and search & evaluation teams in their workflows
- Industry shifts driving demand for in-licensed assets
- How AI augments BD teams to intelligently streamline their work, from competitive benchmarking to program assessments to commercial forecasting
Additional resources
Jay Andersen, a pioneer in pharmaceutical decision-making, shared some lessons learned from developing portfolio management and probability assessment approaches.
Founding Members Chiesi, BIAL Lead Initial Funding; Landmark Bio, Uncommon Cures Join Clinical Development Network; DVLP Medicines, Vibe Bio to Provide Integrated AI-based Solutions
Pharma's business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company's future. As the biopharma industry navigates an increasingly complex marketplace, traditional approaches to identifying and evaluating potential drug candidates are showing signs of strain.
Biopharma business development and scientific teams are under a lot of pressure to identify the next big program for their indication and strategy.
I recently sat down with a Top 20 pharmaceutical company to discuss their goals and struggles for the year ahead and how pharma portfolio analytics fits in.
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
Uncover new possibilities with VibeOne
Learn how VibeOne can help you discover your next indication or identify high potential development opportunities in your portfolio.
